Medicare AdvantageCoverageMedium impact
MA06.029b, Therapeutic Drug Monitoring for Antidepressants, Antipsychotics, and Antiepileptics
Independence Blue Cross·Psychiatry, Neurology, Family Medicine +1 more·Pharmacy
Effective date
Jun 25, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA06.029b for Therapeutic Drug Monitoring for Antidepressants, Antipsychotics, and Antiepileptics has been reissued and updated. This policy affects coverage and monitoring requirements for psychiatric and neurologic medications.
Action Required
Before June 25, 2025: Billing team should review the updated MA06.029b policy at the provided URL to understand specific changes to therapeutic drug monitoring requirements for antidepressants, antipsychotics, and antiepileptics. Update billing procedures and provider documentation requirements accordingly for Medicare Advantage patients receiving these medications.